COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. ("ENZC" or the "Company")...
SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability...
Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New Class” of Malaria...
First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV...
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials...
Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in CanadaPDS Biotech’s proprietary combination of Versamune®...
Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve...
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects...
The two industry leaders focus on navigating the biotech industry and immuno-oncology researchLEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) --...
First state license is a key achievement as Blue Water continues to expand its business into commercial activitiesCINCINNATI, July 06, 2023...
Collaboration expands Carrick’s clinical-stage Oncology programDUBLIN, Ireland and BOSTON, July 06, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical...
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge...
CINCINNATI, July 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology...
Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in...
Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year....
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a...
Experts in vaccination from Germany, France and Spain, invited by the Bamberg Foundation, met in Berlin to discuss the key...
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab...